Apellis Pharmaceuticals, Inc.
COO
2024-01-16–present
6 appearances
Latest appearance 2024-09-30
Adam Townsend
Apellis Pharmaceuticals, Inc.
COO
Apellis Pharmaceuticals, Inc.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Adam Townsend
Adam Townsend is recorded as COO at Apellis Pharmaceuticals, Inc.. Apellis Pharmaceuticals, Inc. reported in an 8-K filed January 13, 2025 that Adam Townsend resigned as Chief Operating Officer, effective February 21, 2025. Apellis Pharmaceuticals, Inc. reported in an 8-K filed January 22, 2024 that Adam Townsend was appointed Chief Operating Officer, effective January 16, 2024. The proxy statement of Apellis Pharmaceuticals, Inc. reports total compensation of $3,956,053 for Adam Townsend in fiscal 2024, including a base salary of $542,732. Disclosed compensation is on record for 5 fiscal years. Adam Townsend has spoken on 6 earnings calls across 1 company, most recently for Apellis Pharmaceuticals, Inc. on September 30, 2024.
“On January 10, 2025, the Company and Adam Townsend mutually agreed that Mr. Townsend will resign as the Company’s Chief Operating Officer effective as of February 21, 2025 (the “Separation Date”).”
“On January 16, 2024, the Board of Directors of Apellis Pharmaceuticals, Inc. (the "Company") appointed Adam Townsend, the Company's Chief Commercial Officer, to serve as the Company's Chief Operating Officer, effective immediately.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Apellis Pharmaceuticals, Inc.
COO
SEC 8-K
Current2024-01-16–present
-
Apellis Pharmaceuticals, Inc.
Source not stated
Current -
Apellis Pharmaceuticals, Inc.
COO
SEC 8-K
2024-01-16–2025-02-21
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Apellis Pharmaceuticals, Inc. | Chief Commercial Officer | $542,732 | $3,956,053 |
| 2023 | Apellis Pharmaceuticals, Inc. | Chief Commercial Officer | $484,577 | $3,714,246 |
| 2022 | Apellis Pharmaceuticals, Inc. | Chief Commercial Officer | $460,013 | $3,096,029 |
| 2021 | Apellis Pharmaceuticals, Inc. | Chief Commercial Officer | $448,269 | $2,640,819 |
| 2020 | Apellis Pharmaceuticals, Inc. | Chief Commercial Officer | $430,038 | $2,901,007 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
-
-
Earnings call
Apellis Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Apellis Pharmaceuticals, Inc.
-
Earnings call
Apellis Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Apellis Pharmaceuticals, Inc.
-
Earnings call
Apellis Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Apellis Pharmaceuticals, Inc.
-
-
Earnings call
Apellis Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Apellis Pharmaceuticals, Inc.
-
Earnings call
Apellis Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Apellis Pharmaceuticals, Inc.
-
Earnings call
Apellis Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Apellis Pharmaceuticals, Inc.